ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1876 • ACR Convergence 2021

    A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome

    Yiming Luo1, Ertugrul Bolek1, Kaitlin Quinn2, Kristina Wells3, Emily Rose4, Emily Rominger1, Levent Kilic5, Omer Karadag6, Cindy Clark1, Alicia Livinski1, Peter Grayson7 and Marcela Ferrada1, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Case Western, Cleveland Heights, OH, 5Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 6Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, 7National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare and poorly understood entity with clinical features of both relapsing polychondritis (RP)…
  • Abstract Number: 1880 • ACR Convergence 2021

    Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young3, Cristina Burroughs4 and Peter Merkel5, 1Vanderbilt University Medical Center, Franklin, TN, 2University of California Los Angeles, West Hills, CA, 3Vasculitis Foundation, Kansas City, MO, 4Health Informatics Institute, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
  • Abstract Number: 1878 • ACR Convergence 2021

    Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients

    Diana Prieto-Peña1, Pilar Bernabeu2, Paloma Vela3, Javier Narvaez4, Jesús Carlos Fernández-López5, Mercedes Freire6, Beatriz González-Alvarez7, Roser Solans-Laqué8, José Luis Callejas9, Norberto Ortego10, Carlos Fernández-Díaz11, Esteban Rubio Romero12, Salvador Garcia-Morillo13, Mauricio Minguez14, Cristina Carballido14, Eugenio De Miguel15, Sheila Melchor16, Eva Salgado17, Beatriz Bravo18, Susana Romero-Yuste19, Juan Salvatierra20, Cristina Hidalgo21, Sara Manrique Arija22, Carlos Romero Gomez23, Patricia Moya24, Noelia Álvarez-Rivas25, Javier Mendizábal-Mateos26, Francisco Ortiz-Sanjuán27, Ivan Perez De Pedro28, Jose L Alonso-Valdivielso29, Laura Perez-Sanchez30, Rosa Roldan31, Nagore Fernandez-Llanio32, Ricardo Gómez de la Torre33, Silvia Suarez33, Mara Jess Montesa Cabrera34, MONICA DELGADO SANCHEZ35, Javier Loricera1, Belén Atienza-Mateo36, Miguel Ángel gonzalez-Gay37 and Ricardo Blanco38, 1Hospital Universitario Marqués de Valdecilla, santander, Spain, 2Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Hospital Universitario Juan Canalejo, A Coruña, Spain, 6Rheumatology Service. CHU Coruña, La Coruña, Spain, 7H. NªSª de la Candelaria, Tenerife, Spain, 8Hospital Vall d'Hebron, Barcelona, Spain, 9Hospital San Cecilio, Granada, Spain, 10Medicine Department, Universidad de Granada, Granada, Spain, 11Hospital Universitario Reina Sofía, Murcia, Spain, 12HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, Seville, Spain, 13H Virgen del Rocio, Sevilla, Spain, 14H. San Juan, Alicante, Spain, 15Hospital Universitario La Paz, Madrid, Spain, 16H. 12 de Octubre, Madrid, Spain, 17Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 18Hospital Universitario Virgen de las Nieves, Granada, Spain, 19Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 20H San Juan, Alicante, Spain, 21Hospital Universitario Salamanca, Salamanca, Spain, 22Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 23H. Regional de Malaga, Malaga, Spain, 24Hospital Sant Pau, Barcelona, Spain, 25Hospital San Agustín, Aviles, Spain, 26H. Navarra, Navarra, Spain, 27H. La Fe, Valencia, Spain, 28H. Carlos Haya, Malaga, Spain, 29H. Burgos, Burgos, Spain, 30IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 31H. Reina Sofia, Cordoba, Spain, 32H. Arnau de Vilanova, Valencia, Spain, 33H. Asturias, Oviedo, Spain, 34Hospital Universitario Nuestra Seora de la Candelaria, Santa Cruz de Tenerife, Spain, 35H NªSª Candelaria, Tenerife, Spain, 36Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 37Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 38Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…
  • Abstract Number: 1875 • ACR Convergence 2021

    Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole

    Manuela Osorio1, Tulio Lopera1, Teresita Coneo2, Isabel Velásquez-Giraldo2, Ruben Vargas2, Adriana Lucía Vanegas-García3, Mauricio Rojas2, Gloria Vasquez4 and Carlos Muñoz-Vahos5, 1Universidad de Antioquia, Medellin, Colombia, 2Universidad de Antioquia, Medellín, Colombia, 3Division of rheumatology, Universidad de Antioquia – Hospital San Vicente Fundación, Medellín, Colombia, 4Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, 5Hospital San Vicente Fundación, Medellín, Colombia

    Background/Purpose: The Vasculopathy induced by Cocaine-Levamisole (VICOL) is a recently described vasculopathy characterized by the presence of tissue necrosis. One of the possible mechanisms associated…
  • Abstract Number: 1869 • ACR Convergence 2021

    The Role of Faecal Calprotectin in IgA Vasculitis

    Alojzija Hocevar1, Matija Bajzelj1, Matija Tomšič2 and Katja Lakota3, 1UKC Ljubjana, Ljubjana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Llubljana, Slovenia

    Background/Purpose: Gastrointestinal involvement (GI) is associated with significant morbidity in acute IgA vasculitis (IgAV). Besides the abdominal pain, bowel ischemia could lead to bleeding, perforation,…
  • Abstract Number: 1881 • ACR Convergence 2021

    Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease

    Youjin Jung and Eun bong Lee, Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: Behcet's disease (BD) is characterized by hyper-inflammatory response to trauma, which is called the pathergy phenomenon. Therefore, there are concerns about post-operative complications when…
  • Abstract Number: 1888 • ACR Convergence 2021

    Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD

    Gözde Kübra Yardımcı1, Bayram Farisogulları2, Gizem Ayan1, Levent Kilic1, Sule Apraş Bilgen1 and Omer Karadag3, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, 3Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey

    Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…
  • Abstract Number: 1892 • ACR Convergence 2021

    Promotion of Autoimmune Arthritis via Tryptophan Metabolism and Production of the Bacterial-Derived Tryptophan Metabolite Indole

    Brandon Trent1, Meagan Chriswell2, Widian Jubair1 and Kristine Kuhn1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2UC Denver SOM, Denver, CO

    Background/Purpose: Significant changes in gut bacterial richness and diversity occur during the development of inflammatory arthritis, in both murine models and human patients; however, the…
  • Abstract Number: 1890 • ACR Convergence 2021

    Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis

    Hannah Nelson1, Ellen Gravallese2, Julia Charles1 and Christian Jacome-Galarza1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…
  • Abstract Number: 1887 • ACR Convergence 2021

    Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment

    Maria Caterina Lagdameo1, Hyungrok Do2 and Johannes Nowatzky1, 1Division of Rheumatology, New York University School of Medicine, New York, NY, 2Department of Population Health, NYU School of Medicine, New York

    Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…
  • Abstract Number: 1872 • ACR Convergence 2021

    Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy

    Moein Amin1, Takashi Shimoyama2, Ken Uchino1, Leonard Calabrese1 and Rula Hajj-Ali3, 1Cleveland Clinic, Cleveland, OH, 2Nippon Medical School, Tokyo, Japan, 3Cleveland Clinic, Hunting Valley, OH

    Background/Purpose: Establishing the diagnosis of Primary central nervous system vasculitis CNSV is challenging. In this study we aimed to investigate distinguishing primary CNSV compared to…
  • Abstract Number: 1898 • ACR Convergence 2021

    Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis

    Sara Tedeschi1, Weixing Huang1, Kazuki Yoshida1 and Daniel Solomon2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Acute calcium pyrophosphate (CPP) crystal arthritis, also known as pseudogout, causes an acute inflammatory arthritis that shares clinical similarities with gout. We investigated the…
  • Abstract Number: 1901 • ACR Convergence 2021

    Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project

    Yvonne Golightly1, Carolina Alvarez1, Marian Hannan2, Lucy Gates3, Becki Cleveland4, Amanda Nelson1 and Leigh Callahan5, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, 3University of Southampton, Southampton, United Kingdom, 4Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 5University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC

    Background/Purpose: Foot symptoms (i.e., pain, aching, and stiffness [PAS]) are common in middle-aged to older adults and are linked to restricted physical activity, poorer physical…
  • Abstract Number: 1900 • ACR Convergence 2021

    Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy

    James O'Dell1, Tuhina Neogi2, Michael Pillinger3, Paul Palevsky4, Jeff Newcomb1, Mary Brophy5, Hongsheng Wu5, Annie Davis-Karim6, Ryan Ferguson5, David Pittman6, Robert Terkeltaub7, Amy Cannella1, Bryant England1, Lindsay Helget1, Ted Mikuls1 and Tomas Taylor8, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA, 3New York University Grossman School of Medicine, New York,, NY, 4Pittsburgh University, Pittsburgh, PA, 5Boston VA, Boston, MA, 6Albuquerque VA, Albuquerque, NM, 7VA/UCSD, San Diego, CA, 8White River Junction VA, White River Junction, VT

    Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
  • Abstract Number: 1899 • ACR Convergence 2021

    Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study

    Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1, Tuhina Neogi2 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA

    Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
  • « Previous Page
  • 1
  • …
  • 708
  • 709
  • 710
  • 711
  • 712
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology